Scarica l'app Stockscreener
20.34
3.56%
0.70
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Assenagon Asset Management S.A. Sells 77,023 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 30,000 Shares - MarketBeat
Cullinan Therapeutics (CGEM) investor group discloses 6,491,123-share position - Stock Titan
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Cullinan Therapeutics (CGEM): T. Rowe Price reports 6.2% ownership stake - Stock Titan
CGEM (CGEM) insider to sell 30,000 shares after stock option exercise - Stock Titan
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Op - Benzinga
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - MarketBeat
CGEM Maintains Outperform Rating -- Price Target Raised to $42.0 - GuruFocus
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $42.00 - MarketBeat
Cullinan Therapeutics (CGEM) Shares Rise 6% Premarket on Positive Lung Cancer Trial Results - GuruFocus
New Taiho, Cullinan data heats up lung cancer drug battle - Yahoo Finance
Show Me The Money: Did You Miss CGEM's Rally? Here's What Comes Next - RTTNews
Cullinan rises on trial win for lung cancer drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan: REZILIENT3 Phase 3 Interim Shows Improved PFS for Zipalertinib + Chemo - TradingView
Cullinan Therapeutics, Inc. $CGEM Shares Bought by The Manufacturers Life Insurance Company - MarketBeat
Cullinan Therapeutics Says Phase 3 Trial of Experimental Lung Cancer Drug Met Primary Endpoint - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
Zipalertinib trial meets primary endpoint in lung cancer study - Investing.com Nigeria
Zipalertinib trial meets primary endpoint in lung cancer study By Investing.com - Investing.com Australia
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
HC Wainwright Issues Pessimistic Outlook for CGEM Earnings - MarketBeat
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews
Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com - Investing.com UK
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 52-Week HighStill a Buy? - MarketBeat
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Oncology stock hits 52-week high at 19.43 USD - Investing.com
Cullinan Therapeutics (CGEM) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Dimensional Fund Advisors LP Has $12.87 Million Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results - MarketBeat
Cullinan Therapeutics Inc (CGEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cullinan Therapeutics (CGEM): State Street discloses 3.67M-share, 6% ownership stake - Stock Titan
The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following FDA-Backed Phase 2 CLN-049 Trial - Yahoo Finance
Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Cullinan Therapeutics, Inc. Stock 12‑Month Price Target Raised to $33, Implies 87% Upside - TradingView
Cullinan Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cullinan Therapeutics Q2 net loss narrows - TradingView
Cullinan Therapeutics 3Q 2026: Revenue $0 Net loss $53.7M, EPS $(0.81) — 10-Q Summary - TradingView
Cullinan Therapeutics: Q2 Earnings Snapshot - Barchart.com
CGEM: Pipeline advances and strong cash position support growth and late-stage clinical milestones - TradingView
Cullinan Therapeutics reports Q2 2026 net loss of $53.7M, cash and investments $356.0M - TradingView
BRIEF-Cullinan Therapeutics Q2 Operating Income USD -57.254 Million Vs. IBES Estimate USD -57.1 Million - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - globenewswire.com
Cullinan Oncology earnings up next: Can pipeline justify cash burn? By Investing.com - Investing.com UK
CGEM|Cullinan Therapeutics Inc|Price:16.260|Chg%:-0.240 - tradingkey.com
Cullinan Therapeutics (CGEM) Slides 5.8% as Pipeline-Focused Biotech Faces Key Support Test at $15.67Unusual Put Volume - dars.gov.et
Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%Here's What Happened - MarketBeat
CGEM Q2'26 Earnings: revenue estimate is 0 USD - TradingView
BTIG Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $39 - moomoo.com
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $39.00 - MarketBeat
Cullinan Therapeutics stock rises on FDA meeting for CLN-049 By Investing.com - Investing.com Canada
Cullinan Therapeutics stock rises on FDA meeting for CLN-049 - Investing.com
Why is Cullinan Therapeutics stock climbing today? By Investing.com - Investing.com Canada
Cullinan Therapeutics (CGEM) Advances AML Treatment with FDA Fee - GuruFocus
Cullinan Therapeutics advances CLN-049 to Phase 2 after positive FDA feedback - Traders Union
Cullinan Therapeutics Announces Positive FDA Feedback for CLN-049 and Plans Potentially Registrational Phase 2 Study in Relapsed/Refractory AML - Quiver Quantitative
Cullinan Therapeutics Announces Positive End-of-Phase 1 - GlobeNewswire
Cullinan Therapeutics gets FDA nod to start Pha... - Pluang
Cullinan Therapeutics Inc (CGEM) Institutional Confidence - TradingKey
Cullinan Therapeutics Inc (CGEM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cullinan Therapeutics Inc (CGEM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cullinan Therapeutics Inc (CGEM) Valuation: PE, PB & Fair Value Analysis - TradingKey
CGEM|Cullinan Therapeutics Inc|Price:17.775|Chg%:+0.675 - TradingKey
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):